Related Experiment Video

Updated: Apr 26, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

8.5K

New therapies for hepatitis C: considerations in patients with renal impairment

Sarah Zimner-Rapuch1, Nicolas Janus, Gilbert Deray

  • 1Service ICAR, Service de Néphrologie, Groupe Hospitalier Pitié-Salpêtrière, 47-83 Boulevard de l'Hôpital, 75013, Paris, France, sarah.rapuch@psl.aphp.fr.

Drugs
|July 26, 2014
PubMed

Insights

Treating Hepatitis C virus (HCV) in patients with chronic kidney disease is crucial. This review provides guidelines for using new HCV therapies, addressing dosage adjustments for renal impairment.

Area of Science:

  • Hepatology
  • Nephrology
  • Virology

Background:

  • Hepatitis C virus (HCV) infection poses significant health risks, including liver failure and hepatocellular carcinoma.
  • HCV can exacerbate existing kidney disease in patients with renal dysfunction.
  • Effective HCV treatment is essential for patients with impaired renal function.

Purpose of the Study:

  • To review and synthesize available data on the use of new direct-acting antiviral (DAA) therapies for HCV in patients with chronic kidney disease (CKD).
  • To propose practical guidelines for dosage adjustments of novel HCV medications based on renal function.
  • To address the limited information currently available for this vulnerable patient population.

Main Methods:

  • A comprehensive literature search was conducted to identify studies on HCV treatment in patients with renal dysfunction.
  • Data regarding the efficacy and safety of new HCV therapies, including dosage recommendations for varying degrees of renal impairment, were extracted.
  • Information was synthesized to develop evidence-based guidelines.

Main Results:

  • New direct-acting antiviral (DAA) regimens offer effective HCV treatment options.
  • Limited data exist regarding specific dosage adjustments for many new HCV drugs in patients with chronic kidney disease (CKD).
  • Some DAAs may require dose modifications, while others can be used without adjustment, depending on the specific drug and severity of renal impairment.

Conclusions:

  • Guidelines are proposed for the use of new HCV therapies in patients with CKD, focusing on necessary dosage adjustments.
  • Further research is needed to establish definitive dosing recommendations for all novel HCV treatments in renally impaired populations.
  • Optimizing HCV treatment in CKD patients is critical to prevent progression of both liver and kidney disease.

More Related Videos

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

20.3K
A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

2.2K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
380
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
78
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
379
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
271
Renal Drug Excretion: Overview01:15

Renal Drug Excretion: Overview

As primary excretory organs, the kidneys maintain homeostasis by removing waste substances from the bloodstream. They comprise over a million units called nephrons, which serve as the kidney's functional units.
A nephron consists of two primary structures: the renal corpuscle and the renal tubule. The renal corpuscle contains the glomerulus, a network of capillaries where the first step of renal excretion, glomerular filtration, occurs. Blood pressure forces water, ions, and small molecules...
1.1K
Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in...
414